Rad51L3-RFFL: A Potential Drug Target and Biomarker (G100529207)

Target Name: RAD51L3-RFFL

NCBI ID: G100529207

Other Name(s): RAD51L3-RFFL readthrough

Rad51L3-RFFL: A Potential Drug Target and Biomarker

Rad51L3-RFFL (respiratory factor-like protein L3) is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The rad51 gene is a member of the TOW gene family, which is known for the regulation of cell growth and differentiation. The rad51 gene encodes a protein that contains a unique domain that is similar to that of the transcription factor RFFL. This domain is responsible for the protein's ability to interact with DNA and regulate gene expression.

Rad51L3-RFFL has been shown to play a role in a number of important biological processes, including cell proliferation, apoptosis, and inflammation. It has also been shown to be involved in the development and progression of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

As a potential drug target, Rad51L3-RFFL is of interest because of its ability to interact with a variety of different molecules and because it has been shown to be involved in the development and progression of a number of diseases. This makes it an attractive target for research and development of new treatments.

The rad51 gene is located on chromosome 19 and has been shown to encode a protein of 21 kDa. The protein is composed of a unique N-terminal domain, a catalytic domain, and a C-terminal domain. The N-terminal domain is responsible for the protein's ability to interact with DNA and the catalytic domain is responsible for the protein's ability to catalyze the transfer of a phosphate group to DNA. The C-terminal domain is responsible for the protein's ability to interact with and regulate the activity of other proteins.

The rad51 gene has been shown to encode a protein that is similar to that of the transcription factor RFFL. RFFL is a protein that is expressed in a variety of tissues and is involved in the regulation of gene expression. It is composed of a unique N-terminal domain, a catalytic domain, and a C-terminal domain. The N-terminal domain is responsible for the protein's ability to interact with DNA and the catalytic domain is responsible for the protein's ability to catalyze the transfer of a phosphate group to DNA. The C-terminal domain is responsible for the protein's ability to interact with and regulate the activity of other proteins.

Rad51L3-RFFL has been shown to play a role in the regulation of gene expression and has been implicated in the development and progression of a number of diseases. For example, studies have shown that high levels of Rad51L3-RFFL are associated with the development of cancer and that inhibiting its activity can lead to the regression of cancer tumors.

In addition to its role in cancer, Rad51L3-RFFL is also implicated in the development and progression of other diseases, including neurodegenerative diseases and autoimmune disorders. For example, studies have shown that Rad51L3-RFFL is involved in the development of neurodegenerative diseases, such as Alzheimer's disease, and that inhibiting its activity can lead to the regression of these diseases.

As a potential drug target, Rad51L3-RFFL is of interest because of its ability to interact with a variety of different molecules and because it has been shown to play a role in the development and progression of a number of diseases. This makes it an attractive target for

Protein Name: RAD51L3-RFFL Readthrough

More Common Targets